Omeros CorpNASDAQ:OMER
- LAST PRICE3.8600
- TODAY'S CHANGE (%)-0.0500 (-1.2788%)
- Bid / Lots3.6000/ 18
- Ask / Lots4.0500/ 56
- Open / Previous Close3.8700 / 3.9100
- Day Range
- 52 Week Range
- Volume289,323
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 1924 | 3.87 |
| 09:34 ET | 3523 | 3.91 |
| 09:38 ET | 19061 | 3.91 |
| 09:39 ET | 11872 | 3.87 |
| 09:41 ET | 400 | 3.87 |
| 09:45 ET | 750 | 3.889 |
| 09:50 ET | 100 | 3.879 |
| 09:52 ET | 600 | 3.889 |
| 09:54 ET | 500 | 3.87 |
| 09:56 ET | 181 | 3.875 |
| 09:57 ET | 600 | 3.87 |
| 10:01 ET | 1050 | 3.8701 |
| 10:03 ET | 300 | 3.89 |
| 10:10 ET | 100 | 3.909 |
| 10:12 ET | 400 | 3.895 |
| 10:14 ET | 300 | 3.899 |
| 10:15 ET | 1500 | 3.939 |
| 10:17 ET | 500 | 3.935 |
| 10:21 ET | 2125 | 3.979 |
| 10:24 ET | 800 | 4 |
| 10:26 ET | 800 | 4.035 |
| 10:28 ET | 2179 | 4.04 |
| 10:30 ET | 650 | 4.0301 |
| 10:32 ET | 2566 | 4.0396 |
| 10:33 ET | 200 | 4.0295 |
| 10:35 ET | 100 | 4.025 |
| 10:37 ET | 200 | 4.025 |
| 10:39 ET | 2364 | 4.025 |
| 10:44 ET | 260 | 4.02 |
| 10:46 ET | 300 | 4.01 |
| 10:51 ET | 400 | 4 |
| 10:57 ET | 600 | 3.97 |
| 11:00 ET | 400 | 3.975 |
| 11:02 ET | 100 | 3.975 |
| 11:04 ET | 22461 | 3.93 |
| 11:06 ET | 100 | 3.935 |
| 11:08 ET | 11166 | 3.89 |
| 11:09 ET | 10437 | 3.8 |
| 11:13 ET | 200 | 3.82 |
| 11:15 ET | 200 | 3.84 |
| 11:18 ET | 4578 | 3.82 |
| 11:20 ET | 4289 | 3.81 |
| 11:24 ET | 200 | 3.81 |
| 11:29 ET | 500 | 3.81 |
| 11:36 ET | 100 | 3.795 |
| 11:44 ET | 3825 | 3.825 |
| 11:45 ET | 100 | 3.825 |
| 11:49 ET | 1300 | 3.83 |
| 11:51 ET | 600 | 3.83 |
| 11:56 ET | 2796 | 3.8201 |
| 11:58 ET | 650 | 3.815 |
| 12:02 ET | 1000 | 3.78 |
| 12:03 ET | 200 | 3.78 |
| 12:05 ET | 400 | 3.785 |
| 12:09 ET | 1728 | 3.78 |
| 12:14 ET | 400 | 3.7715 |
| 12:16 ET | 800 | 3.77 |
| 12:18 ET | 1900 | 3.795 |
| 12:21 ET | 200 | 3.795 |
| 12:23 ET | 100 | 3.795 |
| 12:32 ET | 500 | 3.795 |
| 12:34 ET | 2060 | 3.808 |
| 12:36 ET | 200 | 3.81 |
| 12:38 ET | 100 | 3.805 |
| 12:39 ET | 509 | 3.8 |
| 12:45 ET | 700 | 3.805 |
| 12:48 ET | 200 | 3.805 |
| 12:52 ET | 600 | 3.81 |
| 12:56 ET | 300 | 3.809 |
| 12:59 ET | 700 | 3.809 |
| 01:01 ET | 300 | 3.809 |
| 01:03 ET | 400 | 3.809 |
| 01:06 ET | 600 | 3.805 |
| 01:08 ET | 3368 | 3.845 |
| 01:10 ET | 200 | 3.845 |
| 01:12 ET | 200 | 3.845 |
| 01:15 ET | 200 | 3.845 |
| 01:17 ET | 300 | 3.849 |
| 01:19 ET | 200 | 3.849 |
| 01:21 ET | 800 | 3.875 |
| 01:24 ET | 400 | 3.875 |
| 01:26 ET | 600 | 3.875 |
| 01:28 ET | 2130 | 3.88 |
| 01:30 ET | 7543 | 3.855 |
| 01:33 ET | 996 | 3.8215 |
| 01:35 ET | 1000 | 3.815 |
| 01:39 ET | 4265 | 3.8 |
| 01:44 ET | 1400 | 3.815 |
| 01:48 ET | 2494 | 3.805 |
| 01:51 ET | 100 | 3.805 |
| 01:53 ET | 200 | 3.805 |
| 01:55 ET | 500 | 3.805 |
| 01:57 ET | 1190 | 3.805 |
| 02:00 ET | 700 | 3.81 |
| 02:02 ET | 800 | 3.805 |
| 02:04 ET | 300 | 3.81 |
| 02:06 ET | 3930 | 3.815 |
| 02:09 ET | 1000 | 3.81 |
| 02:11 ET | 100 | 3.815 |
| 02:13 ET | 2499 | 3.815 |
| 02:15 ET | 1300 | 3.805 |
| 02:18 ET | 200 | 3.805 |
| 02:20 ET | 700 | 3.805 |
| 02:22 ET | 300 | 3.81 |
| 02:27 ET | 100 | 3.815 |
| 02:29 ET | 100 | 3.82 |
| 02:31 ET | 700 | 3.815 |
| 02:36 ET | 1686 | 3.825 |
| 02:40 ET | 204 | 3.835 |
| 02:42 ET | 1517 | 3.85 |
| 02:44 ET | 1700 | 3.87 |
| 02:45 ET | 2660 | 3.85 |
| 02:51 ET | 300 | 3.855 |
| 02:54 ET | 100 | 3.855 |
| 02:56 ET | 303 | 3.855 |
| 02:58 ET | 500 | 3.855 |
| 03:00 ET | 300 | 3.865 |
| 03:03 ET | 300 | 3.865 |
| 03:05 ET | 200 | 3.865 |
| 03:07 ET | 200 | 3.865 |
| 03:09 ET | 400 | 3.865 |
| 03:12 ET | 2000 | 3.855 |
| 03:16 ET | 1300 | 3.85 |
| 03:20 ET | 300 | 3.845 |
| 03:21 ET | 300 | 3.849 |
| 03:23 ET | 300 | 3.849 |
| 03:25 ET | 300 | 3.849 |
| 03:27 ET | 1100 | 3.855 |
| 03:30 ET | 100 | 3.855 |
| 03:32 ET | 2406 | 3.85 |
| 03:36 ET | 1209 | 3.855 |
| 03:38 ET | 300 | 3.855 |
| 03:39 ET | 1000 | 3.855 |
| 03:41 ET | 1052 | 3.855 |
| 03:43 ET | 300 | 3.855 |
| 03:45 ET | 500 | 3.855 |
| 03:48 ET | 900 | 3.855 |
| 03:50 ET | 400 | 3.855 |
| 03:52 ET | 2913 | 3.86 |
| 03:54 ET | 800 | 3.859 |
| 03:56 ET | 2403 | 3.86 |
| 03:57 ET | 3809 | 3.86 |
| 03:59 ET | 5124 | 3.86 |
Jun 4, 2024
Omeros Announces Webcast Details for Annual Meeting of Shareholders, from 9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Omeros Shares Rise on Balance Sheet Strengthening, from 11:33AM ET on Monday Jun 03, 2024 by Dow Jones
11:33AM ET on Monday Jun 03, 2024 by Dow JonesOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028, from 9:00AM ET on Monday Jun 03, 2024 by Dow Jones
9:00AM ET on Monday Jun 03, 2024 by Dow Jones
May 16, 2024
DJ Omeros Shares Drop 20% After Wider 1Q Loss, from 10:57AM ET on Thursday May 16, 2024 by Dow Jones
10:57AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
*DJ Omeros 1Q Loss/Shr 63c >OMER, from 4:02PM ET on Wednesday May 15, 2024 by Dow Jones
4:02PM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 230.6M | -1.3x | --- |
Rezolute Inc | 232.4M | -5.0x | --- |
Opthea Ltd | 229.0M | -1.0x | --- |
Acrivon Therapeutics Inc | 228.2M | -2.5x | --- |
Design Therapeutics Inc | 235.0M | -3.7x | --- |
ATAI Life Sciences NV | 236.0M | -5.8x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance
- Michael Jacobsen
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $230.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
